JPMorgan Upgrades Diebold (DBD) to Overweight

January 21, 2021 12:46 AM EST
Get Alerts DBD Hot Sheet
Price: $11.61 +2.65%

Rating Summary:
    6 Buy, 7 Hold, 2 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 22 | Down: 26 | New: 45
Trade Now! 
Join SI Premium – FREE

(Updated - January 21, 2021 5:17 AM EST)

JPMorgan analyst Paul Coster upgraded Diebold (NYSE: DBD) from Neutral to Overweight with a price target of $16.00 (from $10.00).

The analyst comments "DBD is trading at ~6.3x our 2021 PF EBITDA forecast, which is a slight discount to the five-year average of ~6.8x. The discount is warranted, in our view, given modest growth outlook, and elevated debt leverage as the firm manages through COVID-19. That said, we want to own the stock ahead of the firm’s DN Series ramp in 2H21, and the DN NOW program offers a path forward to sustainable 12%+ PF EBITDA margins. We expect DBD to outperform the mean of our coverage over the next 6-12 months."

For an analyst ratings summary and ratings history on Diebold click here. For more ratings news on Diebold click here.

Shares of Diebold closed at $11.18 yesterday.


You May Also Be Interested In





Related Categories

Analyst Comments, Hot Upgrades, Upgrades

Related Entities

JPMorgan